Patent ID: 7223396

Claim:
A method of inhibiting TNFα in a human patient, wherein said human patient has fistulas in Crohn's disease, comprising administering to the human at least four doses provided as single or divided 0.1-50 mg/kg doses of a TNFα-inhibiting amount of an anti-TNFα antibody or antigen-binding fragment thereof, said antibody comprising a human constant region, wherein said anti-TNFα antibody or antigen-binding fragment (i) competitively inhibits binding of A2 (ATCC Accession No. PTA-7045) to human TNFα, and (ii) binds to a neutralizing epitope of human TNFα with an affinity of at least 1×10 8 liter/mole, measured as an association constant (Ka), as determined by Scatchard analysis.